Savvipharm Inc
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
none
Next term end
When these terms end
Held patents by the year their term ends
2026 · 0 end2027 · 02028 · 02029 · 02030 · 0
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,470,672 | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives In force Term ended Oct 7, 2026 · From the USPTO record | In force | Term ended Oct 7, 2026 | From the USPTO record |
Also on record, not counted in the 1: 1 patent in force now held by others · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.